Chemical Communications (RSC) 2026: Generative AI Peptide Drug Design Review Frames the Methods Wave Behind the NK2R Competition and the GLP-1 De Novo Programs
A Chemical Communications (Royal Society of Chemistry) 2026 review on peptide-based drug design using generative AI synthesizes the methods landscape behind the wave of community competitions and pharmaceutical-industry de novo programs that landed in 2026. The review covers ProteoGPT and related protein-language-model architectures, AlphaFold3-based pose prediction, diffusion-model peptide structure generation, and the experimental-validation cycle that turns AI designs into bench-tested candidates. It frames the Tsinghua FRCBS NK2R Peptide Design Competition and the published ultra-long-acting GLP-1 receptor agonist de novo design work as proof-points that the AI-design stack has crossed the threshold from generative novelty to drug-discovery utility. The piece lands as the AI/peptide field tracks toward routine kilogram-scale syntheses (enlicitide PCSK9, others) and into Phase 1/2 candidates inside roughly 18 months from in silico design.